X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration combines Immetas’ proprietary platform for modulating innate immune pathways with GC Biopharma’s messenger RNA (mRNA) therapeutic and lipid nanoparticle (LNP) delivery platforms.
Lead Product(s): mRNA Therapeutic
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: GC Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 12, 2023
Details:
Immetas’ lead program is aimed at designing a series of bi-specific antibodies to regulate inflammation in the tumor microenvironment and overcome resistance to conventional immune checkpoint therapies.
Lead Product(s): Bi-specific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morningside Ventures
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
